Skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus: role of tigecycline.

摘要

In the 1 February 2011 issue of Clinical Infectious Diseases, Lui et al [1] have published the guidelines of the Infectious Diseases Society of America for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Tigecycline, a glycylcycline approved by the Food and Drug Administration (FDA) for complicated skin and skin tissue infections (cSSTIs) in adults, has not been included with the recommended antibiotics [1]. Because I consider these guidelines to be extremely important, I would like to make some comments regarding the potential role of tigecycline in patients with cSSTI due to MRSA.